The Contribution of Lipotoxicity to Diabetic Kidney Disease

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2022 Oct 27

PMID 36291104

Authors

Jeffrey R Schelling

Affiliations

Soon will be listed here.

Abstract

Lipotoxicity is a fundamental pathophysiologic mechanism in diabetes and non-alcoholic fatty liver disease and is now increasingly recognized in diabetic kidney disease (DKD) pathogenesis. This review highlights lipotoxicity pathways in the podocyte and proximal tubule cell, which are arguably the two most critical sites in the nephron for DKD. The discussion focuses on membrane transporters and lipid droplets, which represent potential therapeutic targets, as well as current and developing pharmacologic approaches to reduce renal lipotoxicity.

Citing Articles

Renal Lipid Alterations From Diabetes to Early-Stage Diabetic Kidney Disease and Mitophagy: Focus on Cardiolipin.

Li Z, Wang H, Liu N, Lan X, Xie A, Yuan G J Cell Mol Med. 2025; 29(3):e70419.

PMID: 39936909 PMC: 11816159. DOI: 10.1111/jcmm.70419.

UHRF1 promotes calcium oxalate-induced renal fibrosis by renal lipid deposition via bridging AMPK dephosphorylation.

Sun Y, Li B, Song B, Xia Y, Ye Z, Lin F Cell Biol Toxicol. 2025; 41(1):39.

PMID: 39899077 PMC: 11790803. DOI: 10.1007/s10565-025-09991-9.

Pharmacological Nephroprotection in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus-Clinical Practice Position Statement of the Polish Society of Nephrology.

Adamczak M, Kurnatowska I, Naumnik B, Stompor T, Tylicki L, Krajewska M Int J Mol Sci. 2024; 25(23.

PMID: 39684653 PMC: 11641270. DOI: 10.3390/ijms252312941.

The role of hypoxia-inducible factors 1 and 2 in the pathogenesis of diabetic kidney disease.

Kleibert M, Tkacz K, Winiarska K, Malyszko J, Cudnoch-Jedrzejewska A J Nephrol. 2024; 38(1):37-47.

PMID: 39648258 PMC: 11903585. DOI: 10.1007/s40620-024-02152-x.

Research hotspots and future trends in lipid metabolism in chronic kidney disease: a bibliometric and visualization analysis from 2004 to 2023.

Wang Y, Liu T, Liu W, Zhao H, Li P Front Pharmacol. 2024; 15:1401939.

PMID: 39290864 PMC: 11405329. DOI: 10.3389/fphar.2024.1401939.

References

Takagi S, Li J, Takagaki Y, Kitada M, Nitta K, Takasu T . Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet. J Diabetes Investig. 2018; 9(5):1025-1032. PMC: 6123054. DOI: 10.1111/jdi.12802. View

Ishikawa A, Wada T, Nishimura S, Ito T, Okekawa A, Onogi Y . Estrogen regulates sex-specific localization of regulatory T cells in adipose tissue of obese female mice. PLoS One. 2020; 15(4):e0230885. PMC: 7117686. DOI: 10.1371/journal.pone.0230885. View

Thomas G, Gadegbeku C . Targeting the Standardized Blood Pressure: New Guidelines for Blood Pressure Management in Chronic Kidney Disease. Ann Intern Med. 2021; 174(9):1321-1322. DOI: 10.7326/M21-2571. View

Yoo T, Pedigo C, Guzman J, Correa-Medina M, Wei C, Villarreal R . Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. J Am Soc Nephrol. 2014; 26(1):133-47. PMC: 4279736. DOI: 10.1681/ASN.2013111213. View

Gu W, Wang X, Zhao H, Geng J, Li X, Zheng K . Resveratrol ameliorates diabetic kidney injury by reducing lipotoxicity and modulates expression of components of the junctional adhesion molecule-like/sirtuin 1 lipid metabolism pathway. Eur J Pharmacol. 2022; 918:174776. DOI: 10.1016/j.ejphar.2022.174776. View

Chen N, Mu L, Yang Z, Du C, Wu M, Song S . Carbohydrate response element-binding protein regulates lipid metabolism via mTOR complex1 in diabetic nephropathy. J Cell Physiol. 2020; 236(1):625-640. DOI: 10.1002/jcp.29890. View

Kim Y, Lim J, Kim M, Kim E, Yoon H, Shin S . The Adiponectin Receptor Agonist AdipoRon Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes. J Am Soc Nephrol. 2018; 29(4):1108-1127. PMC: 5875945. DOI: 10.1681/ASN.2017060627. View

Larrinaga G, Varona A, Perez I, Sanz B, Ugalde A, Candenas M . Expression of cannabinoid receptors in human kidney. Histol Histopathol. 2010; 25(9):1133-8. DOI: 10.14670/HH-25.1133. View

Farese Jr R, Walther T . Lipid droplets finally get a little R-E-S-P-E-C-T. Cell. 2009; 139(5):855-60. PMC: 3097139. DOI: 10.1016/j.cell.2009.11.005. View

10.

Wu Y, Lin H, Tao Y, Xu Y, Chen J, Jia Y . Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease. Front Pharmacol. 2022; 13:967317. PMC: 9523214. DOI: 10.3389/fphar.2022.967317. View

11.

Aflaki E, Radovic B, Chandak P, Kolb D, Eisenberg T, Ring J . Triacylglycerol accumulation activates the mitochondrial apoptosis pathway in macrophages. J Biol Chem. 2011; 286(9):7418-28. PMC: 3044998. DOI: 10.1074/jbc.M110.175703. View

12.

Robles N, Villa J, Hernandez Gallego R . Non-Proteinuric Diabetic Nephropathy. J Clin Med. 2015; 4(9):1761-73. PMC: 4600158. DOI: 10.3390/jcm4091761. View

13.

Urahama Y, Ohsaki Y, Fujita Y, Maruyama S, Yuzawa Y, Matsuo S . Lipid droplet-associated proteins protect renal tubular cells from fatty acid-induced apoptosis. Am J Pathol. 2008; 173(5):1286-94. PMC: 2570120. DOI: 10.2353/ajpath.2008.080137. View

14.

Forsblom C, Hiukka A, Leinonen E, Sundvall J, Groop P, Taskinen M . Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care. 2009; 33(2):215-20. PMC: 2809252. DOI: 10.2337/dc09-0621. View

15.

Park F, Potukuchi P, Moradi H, Kovesdy C . Cannabinoids and the kidney: effects in health and disease. Am J Physiol Renal Physiol. 2017; 313(5):F1124-F1132. PMC: 5792153. DOI: 10.1152/ajprenal.00290.2017. View

16.

Qin X, Dong H, Fang K, Lu F . The effect of statins on renal outcomes in patients with diabetic kidney disease: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2017; 33(6). DOI: 10.1002/dmrr.2901. View

17.

Wilson P, Wu H, Kirita Y, Uchimura K, Ledru N, Rennke H . The single-cell transcriptomic landscape of early human diabetic nephropathy. Proc Natl Acad Sci U S A. 2019; 116(39):19619-19625. PMC: 6765272. DOI: 10.1073/pnas.1908706116. View

18.

Wang Z, Jiang T, Li J, Proctor G, McManaman J, Lucia S . Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes. 2005; 54(8):2328-35. DOI: 10.2337/diabetes.54.8.2328. View

19.

Ruggenenti P, Mosconi L, Sangalli F, Casiraghi F, Gambara V, Remuzzi G . Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. Kidney Int. 1999; 55(3):984-94. DOI: 10.1046/j.1523-1755.1999.055003984.x. View

20.

Wanner C, Inzucchi S, Zinman B . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(18):1801-2. DOI: 10.1056/NEJMc1611290. View